OncoMatch/Clinical Trials/NCT06869226
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer
Is NCT06869226 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Camrelizumab + Nab-paclitaxel + Cisplatin for esophageal cancer.
Treatment: Camrelizumab + Nab-paclitaxel + Cisplatin — This is a multicenter phase II clinical study to explore the efficacy, safety, and organ preservation feasibility of camrelizumab in combination with chemotherapy for resectable esophageal squamous carcinoma in patients with histologically and pathologically confirmed resectable esophageal squamous carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1B-CT2 N+ M0, CT3 ANY N M0 (AJCC 8th edition)
Excluded: Stage IV
clinical staging of cT1b-cT2 N+ M0 or cT3, any N, M0 (according to AJCC 8th edition); Presence of locally advanced unresectable (regardless of stage) or metastatic disease (stage IV) [excluded]
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
not having received any previous anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, surgery, etc
Cannot have received: chemotherapy
not having received any previous anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, surgery, etc
Cannot have received: surgery
not having received any previous anti-tumor therapy for esophageal cancer, including radiotherapy, chemotherapy, surgery, etc
Cannot have received: immunosuppressive drugs
Exception: inhaled or topical steroids and adrenocorticotropic hormone replacement at doses >10 mg/day prednisone or equivalent are permissible in the absence of active autoimmune disease
Treatment with immunosuppressive drugs, or systemic hormonal drugs for immunosuppression (doses >10 mg/day prednisone or equivalent) within 2 weeks prior to first use of study drug
Cannot have received: live attenuated vaccine
Received a live attenuated vaccine within 4 weeks prior to first use of study drug
Cannot have received: major surgery
Major surgery or severe trauma within 4 weeks prior to first use of study drug
Lab requirements
Blood counts
WBC ≥3.0×10^9/L; NEUT ≥1.5×10^9/L; PLT ≥100×10^9/L; Hb ≥90g/L
Kidney function
SCr ≤1.5x ULN or creatinine clearance ≥60 ml/min (Cockcroft-Gault formula)
Liver function
TBIL ≤1.5x ULN; AST or ALT ≤2.5x ULN
function of vital organs meets the following requirements...Normal bone marrow reserve function with white blood cell (WBC) ≥3.0×10^9/L; neutrophil count (NEUT) ≥1.5×10^9/L, platelet count (PLT) ≥100×10^9/L, hemoglobin (Hb) ≥90g/L; Normal renal function with serum creatinine (SCr) ≤1.5 times upper limit of normal (ULN) or creatinine clearance ≥60 ml/min (Cockcroft-Gault formula); Normal liver function with total bilirubin (TBIL) ≤1.5 times the upper limit of normal (ULN); and an albumin transaminase (AST) or alanine transaminase (ALT) level ≤2.5 times the upper limit of normal (ULN); Normal coagulation function with International Normalized Ratio (INR) ≤ 1.5 times the upper limit of normal (ULN) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5 times the upper limit of normal (ULN).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify